

Bernard R Chaitman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6805575/publications.pdf>

Version: 2024-02-01

42
papers

18,612
citations

236833

25
h-index

265120

42
g-index

43
all docs

43
docs citations

43
times ranked

16850
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2022, 43, 148-149.	1.0	13
2	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions – proceedings from the CEC Summit 2018. <i>American Heart Journal</i> , 2022, 246, 93-104.	1.2	3
3	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
4	Myocardial infarct size and sex-related angiographic differences in myocardial infarction in nonobstructive coronary artery disease. <i>Coronary Artery Disease</i> , 2021, 32, 603-609.	0.3	4
5	Response by Chaitman et al to Letter Regarding Article, “Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons” <i>Circulation</i> , 2021, 144, e14-e15.	1.6	4
6	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. <i>Circulation</i> , 2021, 144, 1024-1038.	1.6	140
7	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24
8	The year in review: electrocardiogram analysis and acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 824-826.	0.4	0
9	Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 130, 1-6.	0.7	2
10	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
11	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	13.9	310
12	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1619-1628.	13.9	56
13	Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 400-411.	1.2	39
14	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100
15	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005079.	0.9	22
16	ORBITA revisited: what it really means and what it does not?. <i>European Heart Journal</i> , 2018, 39, 963-965.	1.0	14
17	Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials. <i>Journal of Neurology</i> , 2018, 265, 578-585.	1.8	35
18	Exaggerated exercise-induced systolic blood pressure response: arterial baroreceptor sensitivity or carotid stiffness?. <i>European Heart Journal</i> , 2018, 39, 607-609.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology, 2018, 72, 2231-2264.	1.2	2,285
20	Angina and Its Management. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 199-209.	1.0	41
21	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. American Heart Journal, 2017, 190, 135-139.	1.2	26
22	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 985-995.	1.2	52
23	Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial. American Heart Journal, 2016, 173, 108-117.	1.2	30
24	Predicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	1.1	178
25	Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation, 2012, 126, 2115-2124.	1.6	59
26	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
27	Stable angina pectoris: antianginal therapies and future directions. Nature Reviews Cardiology, 2012, 9, 40-52.	6.1	15
28	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	1.0	2,447
29	Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery. JAMA - Journal of the American Medical Association, 2011, 305, 585.	3.8	236
30	Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results. Current Opinion in Cardiology, 2010, 25, 597-602.	0.8	5
31	Do Major Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial Differ by Healthcare System?. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 476-483.	0.9	6
32	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine, 2009, 360, 2503-2515.	13.9	1,705
33	The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. Circulation, 2009, 120, 2529-2540.	1.6	247
34	Should ECG be required in young athletes?. Lancet, The, 2008, 371, 1489-1490.	6.3	5
35	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine, 2007, 356, 1503-1516.	13.9	4,022
36	The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. American Journal of Cardiology, 2007, 99, 208-212.	0.7	70

#	ARTICLE	IF	CITATIONS
37	Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. <i>Clinical Cardiology</i> , 2007, 30, 125-130.	0.7	9
38	Antianginal Efficacy of Omapatrilat in Patients With Chronic Angina Pectoris. <i>American Journal of Cardiology</i> , 2005, 95, 1283-1289.	0.7	17
39	Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, S47-S64.	1.0	43
40	Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1375-1382.	1.2	502
41	ACC/AHA 2002 Guideline Update for Exercise Testing: Summary Article. <i>Circulation</i> , 2002, 106, 1883-1892.	1.6	1,525
42	Newer concepts in the medical management of patients with congestive heart failure. <i>Clinical Cardiology</i> , 1993, 16, 380-390.	0.7	7